AbbVie (ABBV) Soared on Favorable Tailwinds
Carillon Tower Advisers, an investment management company, released its 'Carillon Eagle Growth & Income Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index ended Q1 down 4.3%, marking a turbulent start to 2025. The volatility that began in February was triggered by factors including policy uncertainties, economic deceleration, and AI investment sustainability concerns. The market's first intra-quarter drawdown exceeded 10% in 28 months. Adding to the uncertainty, the 10-year U.S. Treasury yield declined from 4.8% to 4.25%, leading to an equity market rotation favoring defensive sectors, quality stocks, and dividend-yielding equities over growth and momentum-driven investments, with top-performing sectors like energy, healthcare, and consumer staples. Moreover, the quarter saw market participation broaden, with index leadership shifting from mega-cap technology companies to a more diverse base of stocks, as evidenced by the S&P 500® Equal Weight Index's outperformance. Additionally, you can check the fund's top 5 holdings to determine its best picks for 2025.
In its first-quarter 2025 investor letter, Carillon Eagle Growth & Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of AbbVie Inc. (NYSE:ABBV) was 6.74%, and its shares gained 13.84% of their value over the last 52 weeks. On May 19, 2025, AbbVie Inc. (NYSE:ABBV) stock closed at $185.71 per share with a market capitalization of $327.809 billion.
Carillon Eagle Growth & Income Fund stated the following regarding AbbVie Inc. (NYSE:ABBV) in its Q1 2025 investor letter:
"AbbVie Inc. (NYSE:ABBV) issued better than expected initial 2025 guidance and raised the long-term sales outlook for its two most important drugs. The stock also benefited from the broader equity market rotation into the healthcare sector, including into more defensive industries like biopharmaceuticals."
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
AbbVie Inc. (NYSE:ABBV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 85 hedge fund portfolios held AbbVie Inc. (NYSE:ABBV) at the end of the fourth quarter, compared to 68 in the third quarter. While we acknowledge the potential of AbbVie Inc. (NYSE:ABBV) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
In another article, we covered AbbVie Inc. (NYSE:ABBV) and shared the list of best dividend stocks with high yields. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025
NEW YORK, June 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of May 31, 2025, an increase of $1.1 billion from assets under management of $87.5 billion at April 30, 2025. The increase was due to market appreciation of $1.3 billion, partially offset by distributions of $150 million and net outflows of $88 million. Assets Under Management (unaudited) ($ in millions) AUM Net MarketAUM By investment vehicle: 4/30/2025 Flows App/(Dep) Distributions 5/31/2025 Institutional Accounts: Advisory $19,937 $10 $352 - $20,299 Subadvisory 14,091 (19) 306 (57) 14,321 Total Institutional Accounts 34,028 (9) 658 (57) 34,620 Open-end Funds 42,210 (80) 510 (42) 42,598 Closed-end Funds 11,271 1 176 (51) 11,397 Total AUM $87,509 ($88) $1,344 ($150) $88,615 About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore. View original content: SOURCE Cohen & Steers, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Nasdaq, S&P 500 close higher on trade hopes
Both the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) closed slightly higher on Monday; the Dow Jones Industrial Average (^DJI) was flat. Trade talks between the US and China have investors hopeful that a deal could be struck between the two nations. Learn more about today's trading in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Musk's feud with Trump reveals one ugly truth about Tesla stock
You can catch Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. The very public spat that has erupted between Tesla (TSLA) CEO Elon Musk and president Donald Trump has sent shares of the EV maker on a wild, wild ride. Shares are off by 15% over the last five sessions as investors fear Trump will take aim at Musk's various lines of business. Musk also being out of Trump's inner circle also runs counter to the bull thesis that circled Tesla's stock post election. But the dustup between the two powerbrokers brings to light a major problem for Tesla's stock as Musk tries to jumpstart a sagging EV business. There is a big disconnect between Tesla's valuation and what's happening underneath the surface. For example, Tesla's stock is up 12% since October 2022 – yet, consensus EPS estimates for 2025, 2026 and 2027 have plunged 77%, 70% and 71% since then according to new research from JP Morgan auto analyst Ryan Brinkman. Further, the stock is valued at a significant premium to the broader market despite Trump likely doing away with EV tax credits soon. The tax credit has been a driver of Tesla's sales and profits. EV subsidies represent about 52% of Tesla's current profits, Brinkman estimates. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website. Yahoo Finance's Opening Bid is produced by Langston Sessoms All right. Welcome to a new episode of The Opening Bid Podcast. I'm Yahoo! Finance executive editor, Brian Sozzi. And this is our stock of the day. Let's get a minute on that clock. Uh, of course, we're going to start with the Elon Musk feud with President Trump, continuing to unfold, has quieted down a little bit, but nonetheless, it's something to be following because it has impacted Tesla stock. Uh, shares are down by 15% over the last five sessions. Uh, of course, when the president, uh, won the presidency, there was this thought that Elon would help, uh, you know, his closeness or proximity to the president would help get auto taxis approved, and everybody would be using robots. Now that thesis has unwound, as Musk is clearly not in the Trump inner circle. But this is highlighted, uh, this feud has highlighted really two problems with Tesla stock. First, uh, the valuation of the stock versus reality. Uh, have to give a shout out to Ryan Brinkman at JP Morgan. Uh, he notes that, uh, Tesla stock is up 12% since October 22. Yet, consensus EPS estimates, I mean, these are shocking to clients, for 2025, next year and 2027 have plunged by 77%, 70%, and 71%, respectively. These are huge declines at a time where Tesla stock is still high. And the problem number two, as I mentioned, is in fact the valuation. Tesla stock valued about 140 times forward estimated earnings. Uh, the S&P 500 is about 22 times. And if President Trump rolls back those EV tax credits, like, uh, it is expected because of his big beautiful bill, um, Tesla could lose a lot of profits. Brinkman estimates EV subsidies represent about 52% of Tesla's core profits, uh, and theoretically, all those profits would go up in smoke. That's our stock of the day on The Opening Bid Podcast.
